Prentiss Smith & Co. Inc. Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Prentiss Smith & Co. Inc. lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 48,696 shares of the medical equipment provider’s stock after acquiring an additional 130 shares during the quarter. Hologic accounts for about 2.5% of Prentiss Smith & Co. Inc.’s holdings, making the stock its 15th largest position. Prentiss Smith & Co. Inc.’s holdings in Hologic were worth $3,967,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Nomura Holdings Inc. purchased a new position in shares of Hologic in the fourth quarter valued at $352,000. Mather Group LLC. bought a new stake in shares of Hologic in the 1st quarter valued at about $48,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares during the last quarter. Wedmont Private Capital increased its holdings in Hologic by 5.7% during the 1st quarter. Wedmont Private Capital now owns 4,110 shares of the medical equipment provider’s stock valued at $322,000 after purchasing an additional 223 shares during the period. Finally, Ballentine Partners LLC increased its holdings in Hologic by 7.4% during the 1st quarter. Ballentine Partners LLC now owns 3,941 shares of the medical equipment provider’s stock valued at $307,000 after purchasing an additional 273 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.

Hologic Stock Down 1.0 %

HOLX stock traded down $0.85 during midday trading on Monday, hitting $80.72. The company’s stock had a trading volume of 321,221 shares, compared to its average volume of 1,580,957. The firm’s 50-day moving average is $80.94 and its 200-day moving average is $77.74. The company has a market cap of $18.84 billion, a PE ratio of 41.62, a P/E/G ratio of 2.89 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.93 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of a number of research analyst reports. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Mizuho boosted their price target on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus price target of $87.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.